Health Care & Life Sciences » Pharmaceuticals | Jiangsu Hengrui Medicine Co. Ltd.

Jiangsu Hengrui Medicine Co. Ltd. A | Income Statement

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
6,097
7,320
9,160
10,891
13,582
17,181
Cost of Goods Sold (COGS) incl. D&A
1,158
1,356
1,420
1,483
1,901
2,525
Gross Income
4,939
5,963
7,741
9,408
11,681
14,656
SG&A Expense
3,512
4,258
5,313
6,563
8,105
10,593
EBIT
1,426
1,692
2,413
2,875
3,575
4,060
Unusual Expense
-
-
-
-
-
-
Non Operating Income/Expense
6
13
3
-
60
82
Interest Expense
1
1
1
2
2
7
Pretax Income
1,479
1,800
2,562
3,013
3,759
4,499
Income Tax
186
227
338
379
466
438
Consolidated Net Income
1,292
1,573
2,224
2,634
3,293
4,061
Net Income
1,238
1,516
2,172
2,589
3,217
4,066
Net Income After Extraordinaries
1,238
1,516
2,172
2,589
3,217
4,066
Net Income Available to Common
1,238
1,516
2,172
2,589
3,217
4,066
EPS (Basic)
0.34
0.42
0.60
0.71
0.88
0.93
Basic Shares Outstanding
3,641
3,652
3,646
3,658
3,641
4,394
EPS (Diluted)
0.34
0.42
0.59
0.71
0.88
0.93
Diluted Shares Outstanding
3,641
3,652
3,654
3,663
3,641
4,394
EBITDA
1,597
1,905
2,635
3,130
3,896
4,441
Other Operating Expense
1
14
14
29
1
3
Non-Operating Interest Income
26
81
126
141
126
318
Minority Interest Expense
54
57
52
45
76
4

About Jiangsu Hengrui Medicine Co.

View Profile
Address
No. 7 Kunlunshan Road
Lianyungang Jiangsu 222000
China
Employees -
Website http://www.hrs.com.cn
Updated 07/08/2019
Jiangsu Hengrui Medicine Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. Its products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; film and gel.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.